Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics have announced today that Invitrogen, a leading life sciences products and services provider, will become the first company to enter the partnership’s PER.C6® licensing business Vendor Network for monoclonal antibodies and recombinant proteins.
